Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Invesco DB Agriculture Fund (DBA) vs 10X Genomics Inc (TXG) Price & Performance

Invesco DB Agriculture FundTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Invesco DB Agriculture Fund vs 10X Genomics Inc — how do they compare? Invesco DB Agriculture Fund trades at $27.61, while 10X Genomics Inc trades at $58.86 (market cap $7.64B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, Invesco DB Agriculture Fund nearer its low. Which is the better fit depends on your goals.

DBATXG
52-Week High
$28.73$58.57
52-Week Low
$25.44$11.34
Market Cap
$7.64B
Sector
Health
Enterprise Value
$7.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Invesco DB Agriculture Fund

DBA, the Invesco DB Agriculture Fund ETF, trades at $27.62, up 0.69% today, and has shown strong performance with a 5% gain over the past month, outperforming the S&P 500. The technical outlook is bullish based on moving averages, while oscillators are neutral. Recent news highlights agricultural commodity strength, with DBA consolidating near highs amid a bullish trend since 2020, supported by a 3.25% yield and diversified futures exposure.

The outlook for DBA remains positive due to favorable agricultural market conditions and geopolitical factors driving commodity prices. Key risks include sector volatility and management fees. Analyst sentiment is constructive, viewing the ETF as a play on rising agricultural demand, though investors should monitor commodity price fluctuations and global supply chain disruptions.

10X Genomics Inc

TXG is trading at $52.03, up 14.1% in the past 24 hours, reflecting strong momentum. The stock exhibits a bullish technical signal with moving averages supporting upward trends, while RSI levels suggest mild overbought conditions. Fundamentally, the company reported Q2 2026 revenue of $151 million, beating estimates, and has shown consistent earnings beats in recent quarters. Recent news highlights collaborations with Cleveland Clinic and the acquisition of Proteintech Genomics, expanding its multiomics capabilities and reinforcing growth prospects.

The outlook for TXG is cautiously optimistic, driven by earnings outperformance and strategic expansions, but risks include persistent net losses and high valuation multiples. Analyst consensus is mixed with a $46 price target, indicating potential downside from current levels. Investors should weigh revenue growth against profitability challenges and monitor execution on new initiatives for sustained upside.

Returns comparison

Trailing returns across standard periods

About Invesco DB Agriculture Fund

The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.

Read more on DBA

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG